Back |
home / stock / phguf / phguf message board
Subject | By | Source | When |
---|---|---|---|
Pharming Group Is A Good Alternative! 1y Target | dennisv | investorshub | 02/16/2017 11:17:26 AM |
Keep Your Eyes Open! | dennisv | investorshub | 01/24/2017 1:33:02 PM |
Pharming Group Solid Base Built To Support Growing. | dennisv | investorshub | 01/22/2017 4:39:19 PM |
https://finance.yahoo.com/quote/PHARM.AS/community?p=PHARM.AS | dennisv | investorshub | 01/16/2017 1:44:39 PM |
To Be Continued! | dennisv | investorshub | 01/16/2017 1:14:14 PM |
Pharming Group Goes Well! | dennisv | investorshub | 01/09/2017 3:22:42 PM |
FDA Approval Of RUCONEST For Acute Angioedema Attacks | xr_biotech_consult | investorshub | 07/17/2014 6:49:15 AM |
Stock Tracker: Latest Pharming Grp Nv Leid (PHGUF) Headlines Pharming Reports On Preliminary Financi | Stock_Tracker | investorshangout | 03/11/2014 4:06:08 AM |
chartguy89: PHGUF 0.80 Stock Charts $PHGUF 1 Month Chart | chartguy89 | investorshangout | 03/09/2014 9:57:08 AM |
chartguy89: PHGUF Stock Charts Last: -0.03 Friday, February 28, 2014 at 11:43:17 PM $PHGUF 1 | chartguy89 | investorshangout | 03/01/2014 4:43:28 AM |
$PHGUF: BLA Filed For Ruconest, As Anticipated; Reiterate Buy | xr_biotech_consult | investorshub | 04/25/2013 5:35:59 PM |
Santarus and Pharming Announce Submission of RUCONEST Biologics | plumo | investorshub | 04/17/2013 3:16:21 PM |
Santarus and Pharming Announce Submission of RUCONEST Biologics | plumo | investorshub | 04/17/2013 3:16:07 PM |
so this must be around the corner : | xr_biotech_consult | investorshub | 03/03/2013 9:59:21 AM |
after R/S new Target 1.60 | xr_biotech_consult | investorshub | 03/03/2013 9:53:42 AM |
5. Mrz 2013 R/S 1/10 | xr_biotech_consult | investorshub | 03/03/2013 9:52:53 AM |
TARGET 0.16 by ROTH Capital Partners | xr_biotech_consult | investorshub | 01/03/2013 12:16:22 PM |
News, Short Squeeze, Breakout and More Instantly...
Pharming Group Nv Ord Company Name:
PHGUF Stock Symbol:
OTCMKTS Market:
First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST® RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarte...
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHAR...